(Q38605198)

4 September 2017

title

Preclinical and clinical development of a dengue recombinant subunit vaccine (English)

1 reference

4 September 2017

0 references

Susan B Manoff

1

1 reference

4 September 2017

Sarah L George

2

1 reference

4 September 2017

Andrew J Bett

3

1 reference

4 September 2017

Michele L Yelmene

4

1 reference

4 September 2017

Govindarajan Dhanasekaran

5

1 reference

4 September 2017

Linda Eggemeyer

6

1 reference

4 September 2017

Michele L Sausser

7

1 reference

4 September 2017

Sheri A Dubey

8

1 reference

4 September 2017

Danilo R Casimiro

9

1 reference

4 September 2017

David E Clements

10

1 reference

4 September 2017

Timothy Martyak

11

1 reference

4 September 2017

Vidya Pai

12

1 reference

4 September 2017

D Elliot Parks

13

1 reference

4 September 2017

Beth-Ann G Coller

14

1 reference

4 September 2017

language of work or name

English

0 references

publication date

9 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

33

1 reference

4 September 2017

issue

50

1 reference

4 September 2017

page(s)

7126-7134

1 reference

Dengue: a continuing global threat

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

The growing burden of dengue in Latin America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Cost of dengue cases in eight countries in the Americas and Asia: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Dengue and hemorrhagic fever: a potential threat to public health in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Update on the global spread of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

The global distribution and burden of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Refining the global spatial limits of dengue virus transmission by evidence-based consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Pathogenesis of dengue: challenges to molecular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Dengue and dengue haemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Identifying protective dengue vaccines: guide to mastering an empirical process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

The future of dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Vaccines for the prevention of dengue: development update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Next-generation dengue vaccines: novel strategies currently under development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Structure of the dengue virus envelope protein after membrane fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Conformational changes of the flavivirus E glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.101

10.1016/J.VACCINE.2015.09.101

7 January 2021

Identifiers

DOI

1 reference

4 September 2017

1 reference